186 related articles for article (PubMed ID: 36804965)
1. Prediction and Demonstration of Retinoic Acid Receptor Agonist Ch55 as an Antifibrotic Agent in the Dermis.
Dolivo DM; Rodrigues AE; Galiano RD; Mustoe TA; Hong SJ
J Invest Dermatol; 2023 Sep; 143(9):1724-1734.e15. PubMed ID: 36804965
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression.
Dolivo DM; Larson SA; Dominko T
Cytokine Growth Factor Rev; 2017 Dec; 38():49-58. PubMed ID: 28967471
[TBL] [Abstract][Full Text] [Related]
3. Regulation of fibrotic changes by the synergistic effects of cytokines, dimensionality and matrix: Towards the development of an in vitro human dermal hypertrophic scar model.
Chawla S; Ghosh S
Acta Biomater; 2018 Mar; 69():131-145. PubMed ID: 29330036
[TBL] [Abstract][Full Text] [Related]
4. Cellular players in lung fibrosis.
Lekkerkerker AN; Aarbiou J; van Es T; Janssen RA
Curr Pharm Des; 2012; 18(27):4093-102. PubMed ID: 22630084
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow concentrate-induced mesenchymal stem cell conditioned medium facilitates wound healing and prevents hypertrophic scar formation in a rabbit ear model.
Hu CH; Tseng YW; Chiou CY; Lan KC; Chou CH; Tai CS; Huang HD; Hu CW; Liao KH; Chuang SS; Yang JY; Lee OK
Stem Cell Res Ther; 2019 Aug; 10(1):275. PubMed ID: 31462299
[TBL] [Abstract][Full Text] [Related]
7. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.
Lagares D; Santos A; Grasberger PE; Liu F; Probst CK; Rahimi RA; Sakai N; Kuehl T; Ryan J; Bhola P; Montero J; Kapoor M; Baron M; Varelas X; Tschumperlin DJ; Letai A; Tager AM
Sci Transl Med; 2017 Dec; 9(420):. PubMed ID: 29237758
[TBL] [Abstract][Full Text] [Related]
8. Novel Synthetic Polymer-Based 3D Contraction Assay: A Versatile Preclinical Research Platform for Fibrosis.
Kumari J; Wagener FADTG; Kouwer PHJ
ACS Appl Mater Interfaces; 2022 May; 14(17):19212-19225. PubMed ID: 35468292
[TBL] [Abstract][Full Text] [Related]
9. Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury.
Nakamura J; Sato Y; Kitai Y; Wajima S; Yamamoto S; Oguchi A; Yamada R; Kaneko K; Kondo M; Uchino E; Tsuchida J; Hirano K; Sharma K; Kohno K; Yanagita M
Kidney Int; 2019 Mar; 95(3):526-539. PubMed ID: 30661714
[TBL] [Abstract][Full Text] [Related]
10. The pro-fibrotic properties of transforming growth factor on human fibroblasts are counteracted by caffeic acid by inhibiting myofibroblast formation and collagen synthesis.
Mia MM; Bank RA
Cell Tissue Res; 2016 Mar; 363(3):775-89. PubMed ID: 26453399
[TBL] [Abstract][Full Text] [Related]
11. The Scar-in-a-Jar: In Vitro Fibrosis Model for Anti-Fibrotic Drug Testing.
Stebler S; Raghunath M
Methods Mol Biol; 2021; 2299():147-156. PubMed ID: 34028741
[TBL] [Abstract][Full Text] [Related]
12. AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF-β - An in vitro study.
Correia-Sá IB; Carvalho CM; Serrão PV; Machado VA; Carvalho SO; Marques M; Vieira-Coelho MA
Eur J Pharmacol; 2021 Feb; 892():173738. PubMed ID: 33220269
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through nuclear factor erythroid 2-like 2 (NFE2L2) protein and the Smad2/3 pathway.
Zhong L; Hao H; Chen D; Hou Q; Zhu Z; He W; Sun S; Sun M; Li M; Fu X
J Cell Physiol; 2019 Mar; 234(3):2606-2617. PubMed ID: 30317545
[TBL] [Abstract][Full Text] [Related]
14. Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis.
Cheng HT; Huang HC; Lee TY; Liao YH; Sheng YH; Jin PR; Huang KW; Chen LH; Chen YT; Liu ZY; Lin TC; Wang HC; Chao CH; Juang IP; Su CT; Huang KH; Lin SL; Wang J; Sung YC; Chen Y
J Control Release; 2022 Jun; 346():169-179. PubMed ID: 35429575
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
16. FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts.
Dolivo DM; Larson SA; Dominko T
J Dermatol Sci; 2017 Dec; 88(3):339-348. PubMed ID: 28899582
[TBL] [Abstract][Full Text] [Related]
17. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring.
Crawford J; Nygard K; Gan BS; O'Gorman DB
Exp Dermatol; 2015 Feb; 24(2):120-6. PubMed ID: 25421393
[TBL] [Abstract][Full Text] [Related]
18. Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis.
Lu D; Aroonsakool N; Yokoyama U; Patel HH; Insel PA
Mol Pharmacol; 2013 Dec; 84(6):787-93. PubMed ID: 24085841
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA let-7d attenuates hypertrophic scar fibrosis through modulation of iron metabolism by reducing DMT1 expression.
Zhao B; Shi X; Feng D; Han J; Hu D
J Mol Histol; 2023 Feb; 54(1):77-87. PubMed ID: 36705783
[TBL] [Abstract][Full Text] [Related]
20. Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.
Pan H; Chen J; Xu J; Chen M; Ma R
Mol Vis; 2009 Nov; 15():2279-86. PubMed ID: 19936025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
